Elmind Capital LP Buys New Stake in Supernus Pharmaceuticals, Inc. $SUPN

Elmind Capital LP bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 4th quarter, Holdings Channel reports. The institutional investor bought 20,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $994,000.

Several other institutional investors also recently bought and sold shares of SUPN. Torren Management LLC purchased a new position in Supernus Pharmaceuticals during the fourth quarter valued at $49,000. EverSource Wealth Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth $51,000. Smartleaf Asset Management LLC grew its stake in shares of Supernus Pharmaceuticals by 30.8% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 268 shares in the last quarter. Hantz Financial Services Inc. grew its stake in shares of Supernus Pharmaceuticals by 73.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 458 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth $55,000.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 23rd. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $43.58 on Thursday. Supernus Pharmaceuticals, Inc. has a 1-year low of $30.83 and a 1-year high of $59.68. The company has a 50-day moving average of $48.27 and a 200 day moving average of $49.51. The firm has a market capitalization of $2.53 billion, a price-to-earnings ratio of -85.45, a PEG ratio of 0.93 and a beta of 0.55.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.